| Identification | Back Directory | [Name]
Rifamycin Sodium | [CAS]
14897-39-3 | [Synonyms]
Rifamycin SV s
RIFAMYCIN SODIUM
Rifamycinsodiumsal
RIFAMYCIN SV-SODIUM
Rifamycin sodium CRS
RIFAMPICIN SV SODIUM
rifamycin sodium salt
Rifamycin Na USP/EP/BP
Rifamycin SV Monosodium
RIFAMYCIN,MONOSODIUMSALT
RIFAMYCIN SV SODIUM SALT
Rifamycin Sodium USP/EP/BP
RifaMycin SV MonosodiuM salt
RifaMycin, sodiuM salt (1:1)
Rifamycin SV sodium, >=900 IU/mg
RIFAMYCIN SV SODIUM SALT HEXAHYDRATE
Rifamycin SV hexahydrate sodium salt
Rifamycin SV Sodium Salt (Rifaximin EP Impurity C Sodium Salt)
5,6,9,17,19,21-Hexahydroxy-23-Methoxy-2,4,12,16,18,20,22-heptaMethyl-
2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate, monosodium salt
(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-21-(Acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione sodium salt | [EINECS(EC#)]
238-965-7 | [Molecular Formula]
C37H46NNaO12 | [MDL Number]
MFCD00056847 | [MOL File]
14897-39-3.mol | [Molecular Weight]
719.75 |
| Chemical Properties | Back Directory | [Melting point ]
>215°C (dec.) | [storage temp. ]
-20°C Freezer | [solubility ]
ethanol: soluble50mg/mL | [form ]
powder | [color ]
Dark Red | [Water Solubility ]
Soluble in water, alcohol and dimethyl sulfoxide. | [Merck ]
13,8302 | [InChIKey]
DJAAUWJRMPPGDA-HSBICLRHNA-N | [SMILES]
[Na+].CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)cc([O-])c4c3C2=O |
| Hazard Information | Back Directory | [Chemical Properties]
Dark Red Solid | [Uses]
Semi-synthetic antibiotic derived from Rifamycin S. Antibacterial. Potency >900 units (dry basis). | [Biological Activity]
Rifamycin SV inhibits selective (E. coliB. subtilis) bacterial DNA-dependent RNA polymerase by binding to the polymerase β-subunita mechanism similar to rifabutin. It acts as a selective cytochrome P450 3A4 inducer. It is active against Gram-positive bacteria and is moderately active against Gram-negative organisms. | [in vivo]
Rifamycin (5 mg/day; s.c.; 3 days a week) sodium is effective in mice infected with M. tuberculosis, significantly reducing the number of viable bacteria in the body[4].
Rifamycin (12.5-25 mg/kg; peritoneal lavage) sodium can improve the survival rate of rats with experimental intraperitoneal infection and significantly reduce the number of intraperitoneal bacteria and adhesion formation[6].
Rifamycin (5-40 mg/kg; esophageal gavage; once a day, 5 days a week; 4 weeks) sodium shortens oral treatment duration in a mouse model of Mycobacterium ulcerans disease[8].
Rifamycin (0.1 mL; intraaural administration; twice daily; 10 days) sodium does not cause hearing loss in adult or weanling rats[9].
Rifamycin (1 mg i.v. bolus followed by 4 mg i.v. infusion; 70 min) sodium interferes with three major steps of Bile acid metabolism in rats with intravenous Sodium cholate (HY-N0324A) infusion, resulting in a significant decrease in bile acid uptake and excretion[10].
Rifamycin (10-160 mg/kg; s.c.; single dose) sodium is approximately 11 times less effective than Metronidazole (HY-B0318) in a mouse Bacteroides fragilis thigh infection model[11].
| Animal Model: | Male Wistar rats (weight 200-250 g), cecal ligation puncture (CLP)-induced intra-abdominal infection model[6] | | Dosage: | 25 mg/kg, 12.5 mg/kg | | Administration: | Peritoneal lavage | | Result: | Improved survival from 50% in the control group to 91.7% in the 25 mg/kg group and 100% in the 12.5 mg/kg group.
Significantly reduced adhesion formation.
Showed a greater reduction in bacterial counts in peritoneal fluid (25 mg/kg).
|
|
|
|